Elsevier

Gender Medicine

Volume 7, Issue 3, June 2010, Pages 218-229
Gender Medicine

Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid

https://doi.org/10.1016/j.genm.2010.06.004Get rights and content

Abstract

Background: The treatment and prevention of glucocorticoid (GC)-induced osteoporosis have been controversial in premenopausal women during their childbearing years.

Objective: This study assessed the incidence and risk factors for symptomatic vertebral fracture in women of childbearing age newly treated with high-dose GC.

Methods: An observational cohort study was conducted at the rheumatic center of Shimoshizu National Hospital in Chiba, Japan, from 1986 to 2006. The prevalence of symptomatic vertebral fractures, as determined by x-rays, was assessed in premenopausal (aged <50 years) women with collagen vascular disease newly treated with high-dose GC (≥20 mg/d prednisolone equivalent) compared with their counterparts who did not receive GC. Differences in the incidences of vertebral fractures were compared between groups by the Kaplan-Meier method and evaluated by the log-rank test. Hazard ratios (HRs) with 95% CIs were estimated using the Cox proportional hazards regression model.

Results: A total of 373 women were assessed: 292 patients in the high-dose GC treatment group (mean [SD] initial age, 32.4 [8.2] years; initial dose, 43.8 [14.9] mg/d; follow-up time, 124.2 [75.4] months) and 81 patients in the non-GC control group (initial age, 39.3 [7.8] years; follow-up time, 106.5 [79.7] months). Symptomatic vertebral fractures occurred more frequently in the high-dose GC group (11.3%) than in the non-GC group (1.2%). Using the Cox model, the adjusted HR for the high-dose GC group was 13.96 (95% CI, 1.87–104.22) relative to the non-GC group. In the high-dose GC group, Kaplan-Meier analyses revealed that the incidence of fractures in women in their forties was significantly higher in comparison with those in their twenties (P < 0.001) and thirties (P < 0.05), and that the incidence of fractures in those who consumed alcohol (>80 g/wk of pure alcohol) was significantly higher than in those who did not (P < 0.05). The Cox model also revealed that the risk was independently higher with every 10-year increment of initial age (HR = 2.27; 95% CI, 1.46–3.53), with every GC dose increase (HR = 2.28; 95% CI, 1.58–3.31), and with each 1-gram decrease of cumulative GC dose (HR = 0.95; 95% CI, 0.93–0.98).

Conclusions: In this study, high-dose GC use was associated with a significantly high prevalence of symptomatic vertebral fractures in premenopausal women with collagen vascular disease during their childbearing years. However, the fracture risk was relatively low in women of childbearing age, especially those in their twenties and thirties during the early years of treatment.

References (44)

  • S Nagai et al.

    Immunopathology of collagen vascular disease

    Curr Opin Pulm Med.

    (1997)
  • R Ramsey-Goldman et al.

    Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data

    Arthritis Rheum.

    (1999)
  • CS Yee et al.

    Prevalence and predictors of fragility fractures in systemic lupus erythematosus

    Ann Rheum Dis.

    (2005)
  • JA Kanis et al.

    A meta-analysis of prior corticosteroid use and fracture risk

    J Bone Miner Res.

    (2004)
  • TP van Staa

    The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

    Calcif Tissue Int.

    (2006)
  • TP van Staa et al.

    The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis

    Osteoporos Int.

    (2002)
  • T Sugiyama et al.

    Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006

    Endocr J.

    (2009)
  • I Tatsuno et al.

    Agedependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases

    J Clin Endocrinol Metab.

    (2009)
  • I Tatsuno et al.

    High prevalence and early complication of symptomatic vertebral fracture in elderly people treated with high-dose glucocorticoids

    J Am Geriatr Soc.

    (2009)
  • DM Reid et al.

    Efficacy and safety of daily rise-dronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial

    J Bone Miner Res.

    (2000)
  • KG Saag et al.

    Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis

    N Engl J Med.

    (1998)
  • S Wallach et al.

    Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

    Calcif Tissue Int.

    (2000)
  • Cited by (13)

    • Use of corticosteroids is not associated with repeated vertebroplasty or kyphoplasty within one year after the surgery in patient older than 50 years

      2017, Acta Orthopaedica et Traumatologica Turcica
      Citation Excerpt :

      Another concern regarding the relationship between comorbidity and vertebral fracture also remains hotly debatable. In the literature, some reported that chronic obstructive pulmonary disease, autoimmune disease, collagen vascular disease including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic sclerosis (SSc)/mixed connective tissue disease (MCTD), polymyositis/dermatomyositis (PM/DM), and microscopic polyangiitis are related to the risk of vertebral fractures.38–41 But those results are also related to long time steroid usage.

    • Corticotrophins, corticosteroids, and prostaglandins

      2012, Side Effects of Drugs Annual
      Citation Excerpt :

      Treatment and prevention The treatment and prevention of glucocorticoid-induced osteoporosis in premenopausal women have been controversial. In an observational cohort study in Japan, from 1986 to 2006 the incidence and susceptibility factors for symptomatic vertebral fractures were assessed in 292 women of childbearing age (mean 32 years) with collagen vascular diseases newly treated with high-dose glucocorticoids (at least 20 mg/day prednisolone equivalents, mean initial dose 44 mg/day) [16C]. They were followed for a mean of 124 months and were compared with 81 patients who did not take glucocorticoids (mean age 39 years, mean follow-up time 107 months).

    View all citing articles on Scopus
    View full text